PMID- 18363995
OWN - NLM
STAT- MEDLINE
DCOM- 20090210
LR  - 20211020
IS  - 1600-065X (Electronic)
IS  - 0105-2896 (Print)
IS  - 0105-2896 (Linking)
VI  - 222
DP  - 2008 Apr
TI  - Immunotherapy of malignant brain tumors.
PG  - 70-100
LID - 10.1111/j.1600-065X.2008.00603.x [doi]
AB  - Despite aggressive multi-modality therapy including surgery, radiation, and 
      chemotherapy, the prognosis for patients with malignant primary brain tumors 
      remains very poor. Moreover, the non-specific nature of conventional therapy for 
      brain tumors often results in incapacitating damage to surrounding normal brain 
      and systemic tissues. Thus, there is an urgent need for the development of 
      therapeutic strategies that precisely target tumor cells while minimizing 
      collateral damage to neighboring eloquent cerebral cortex. The rationale for 
      using the immune system to target brain tumors is based on the premise that the 
      inherent specificity of immunologic reactivity could meet the clear need for more 
      specific and precise therapy. The success of this modality is dependent on our 
      ability to understand the mechanisms of immune regulation within the central 
      nervous system (CNS), as well as counter the broad defects in host cell-mediated 
      immunity that malignant gliomas are known to elicit. Recent advances in our 
      understanding of tumor-induced and host-mediated immunosuppressive mechanisms, 
      the development of effective strategies to combat these suppressive effects, and 
      a better understanding of how to deliver immunologic effector molecules more 
      efficiently to CNS tumors have all facilitated significant progress toward the 
      realization of true clinical benefit from immunotherapeutic treatment of 
      malignant gliomas.
FAU - Mitchell, Duane A
AU  - Mitchell DA
AD  - Division of Neurosurgery, Department of Surgery, The Preston Robert Tisch Brain 
      Tumor Center, Duke, NC 27710, USA. d.mitchell@duke.edu
FAU - Fecci, Peter E
AU  - Fecci PE
FAU - Sampson, John H
AU  - Sampson JH
LA  - eng
GR  - P50 NS020023/NS/NINDS NIH HHS/United States
GR  - R01 CA235612/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Immunol Rev
JT  - Immunological reviews
JID - 7702118
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Toll-Like Receptors)
SB  - IM
MH  - Adjuvants, Immunologic
MH  - Amyloid beta-Peptides/immunology
MH  - Animals
MH  - Antigen-Presenting Cells/immunology
MH  - Antigens, Neoplasm/*immunology
MH  - Blood-Brain Barrier/immunology
MH  - Brain Neoplasms/*immunology/pathology/therapy
MH  - Cancer Vaccines
MH  - Cell Culture Techniques
MH  - Humans
MH  - Immune Tolerance
MH  - Immunity, Innate
MH  - Immunologic Memory
MH  - Immunologic Surveillance
MH  - Immunotherapy/*methods/trends
MH  - Immunotherapy, Adoptive/methods
MH  - Killer Cells, Lymphokine-Activated
MH  - Lymphocytes, Tumor-Infiltrating/immunology/transplantation
MH  - Mice
MH  - Models, Animal
MH  - Rats
MH  - Toll-Like Receptors/agonists
PMC - PMC3418681
MID - NIHMS396799
EDAT- 2008/03/28 09:00
MHDA- 2009/02/12 09:00
PMCR- 2012/08/14
CRDT- 2008/03/28 09:00
PHST- 2008/03/28 09:00 [pubmed]
PHST- 2009/02/12 09:00 [medline]
PHST- 2008/03/28 09:00 [entrez]
PHST- 2012/08/14 00:00 [pmc-release]
AID - IMR603 [pii]
AID - 10.1111/j.1600-065X.2008.00603.x [doi]
PST - ppublish
SO  - Immunol Rev. 2008 Apr;222:70-100. doi: 10.1111/j.1600-065X.2008.00603.x.